Matt O'Brien
Stock Analyst at Piper Sandler
(2.12)
# 2,598
Out of 4,810 analysts
174
Total ratings
38.19%
Success rate
-9.2%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $94.52 | +74.57% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $24.13 | +11.89% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $1.00 | +100.00% | 6 | Mar 21, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $5.5 → $3.5 | $2.52 | +38.89% | 7 | Mar 6, 2025 | |
| TFX Teleflex | Downgrades: Neutral | $255 → $140 | $128.51 | +8.94% | 5 | Feb 28, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $12 → $13 | $9.91 | +31.18% | 2 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Overweight | $26 | $10.48 | +148.09% | 1 | Feb 24, 2025 | |
| PODD Insulet | Maintains: Overweight | $285 → $310 | $256.43 | +20.89% | 8 | Feb 21, 2025 | |
| PEN Penumbra | Reiterates: Overweight | $250 → $330 | $272.26 | +21.21% | 13 | Feb 19, 2025 | |
| ATRC AtriCure | Maintains: Overweight | $40 → $50 | $32.36 | +54.51% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $16.52 | -3.15% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $6.31 | +216.96% | 8 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $94.23 | +22.04% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $90 | $87.18 | +3.23% | 9 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $9.23 | +30.01% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $100 | $72.35 | +38.22% | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $346.72 | +21.14% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $116.86 | +19.80% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $52.92 | +41.72% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $69.23 | +30.00% | 10 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $82.31 | +9.34% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $12.99 | -7.62% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 → $55 | $17.71 | +210.56% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $48.49 | +64.98% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.05 | +91.57% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $20.97 | +90.75% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.54 | +94.81% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.02 | +341.18% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $97.27 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.82 | +431.91% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $77.80 | +39.78% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.20 | +726.36% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $27.80 | +187.77% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $2.40 | +400.00% | 1 | Jun 24, 2020 |
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $94.52
Upside: +74.57%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $24.13
Upside: +11.89%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.00
Upside: +100.00%
Sight Sciences
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $2.52
Upside: +38.89%
Teleflex
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $128.51
Upside: +8.94%
Alphatec Holdings
Feb 27, 2025
Maintains: Overweight
Price Target: $12 → $13
Current: $9.91
Upside: +31.18%
Beta Bionics
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $10.48
Upside: +148.09%
Insulet
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $256.43
Upside: +20.89%
Penumbra
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $272.26
Upside: +21.21%
AtriCure
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $32.36
Upside: +54.51%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $16.52
Upside: -3.15%
Feb 5, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $6.31
Upside: +216.96%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $94.23
Upside: +22.04%
Dec 11, 2024
Maintains: Overweight
Price Target: $110 → $90
Current: $87.18
Upside: +3.23%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $9.23
Upside: +30.01%
Nov 6, 2024
Maintains: Overweight
Price Target: $80 → $100
Current: $72.35
Upside: +38.22%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $346.72
Upside: +21.14%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $116.86
Upside: +19.80%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $52.92
Upside: +41.72%
Aug 26, 2024
Reiterates: Overweight
Price Target: $90
Current: $69.23
Upside: +30.00%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $82.31
Upside: +9.34%
Aug 9, 2024
Reiterates: Overweight
Price Target: $15 → $12
Current: $12.99
Upside: -7.62%
Aug 2, 2024
Reiterates: Overweight
Price Target: $50 → $55
Current: $17.71
Upside: +210.56%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $48.49
Upside: +64.98%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.05
Upside: +91.57%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $20.97
Upside: +90.75%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.54
Upside: +94.81%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.02
Upside: +341.18%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $97.27
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.82
Upside: +431.91%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $77.80
Upside: +39.78%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.20
Upside: +726.36%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $27.80
Upside: +187.77%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $2.40
Upside: +400.00%